Top-tier general hospital · South China complex-care hub
Established
1946
Beds
3,300+
Annual Volume
75,000+
Guangzhou
Home of Prof. Wu Yi-Long’s precision lung cancer program — multiple studies here have changed international practice.
Guangdong Provincial People’s Hospital is among the strongest comprehensive hospitals in South China; its Guangdong Lung Cancer Institute (Professor Wu Yi-Long’s team) is a global powerhouse in lung cancer care and research — multiple practice-changing phase III studies (ADJUVANT, the CTONG series) originated here.
Its cardiology ranks first nationally, offering unique support for cancer patients with cardiovascular disease; mature day-treatment and continuum-management systems serve oncology patients.
01A global lung cancer research powerhouse
The CTONG study series led by Professor Wu Yi-Long has repeatedly changed international lung cancer guidelines; the precision-treatment paradigm for EGFR-mutant lung cancer was established here.
02Cardio-oncology support
A nationally top-ranked cardiology team supports cardiac assessment, anthracycline cardiotoxicity management and perioperative cardiac-event prevention for cancer patients.
03Lung cancer MDT and continuum care
The institute runs integrated MDTs across medicine, surgery, radiotherapy, imaging and pathology, with deep experience matching rare driver alterations to therapy.
Studies led by Prof. Wu Yi-Long’s team (ADJUVANT, the global ADAURA collaboration) established adjuvant targeted therapy for EGFR-mutant lung cancer, incorporated into NCCN and ESMO guidelines.
Relying on the Guangdong Lung Cancer Institute, it built a full-course management system from screening and molecular profiling to treatment decisions and follow-up, with routine MDT operation.